Wikipedia

Proliferative fasciitis and proliferative myositis

Proliferative fasciitis and proliferative myositis (PF/PM) are rare benign soft tissue lesions (i.e. a damaged or unspecified abnormal change in a tissue) that increase in size over several weeks and often regress over the ensuing 1–3 months.[1] The lesions in PF/PM are typically obvious tumors or swellings. Historically, many studies had grouped the two descriptive forms of PF/PM as similar disorders with the exception that proliferative fasciitis occurs in subcutaneous tissues[2] while proliferative myositis occurs in muscle tissues.[3] In 2020, the World Health Organization agreed with this view and defined these lesions as virtually identical disorders termed proliferative fasciitis/proliferative myositis or proliferative fasciitis and proliferative myositis. The Organization also classified them as one of the various forms of the fibroblastic and myofibroblastic tumors.[4]

Proliferative fasciitis and proliferative myositis
Histopathology of proliferative fasciitis or proliferative myositis
SpecialtyDermatology, General surgery
Usual onsetVery rapid
DurationOften regresses spontaneously within weeks of diagnosis
Treatmentsymptomatic therapy, watchful waiting, surgical resection
PrognosisExcellent
FrequencyExtremely rare

PF/PM lesions have been regarded as a tissue's self-limiting reaction to an injury or unidentified insult rather than an abnormal growth of a clone of neoplastic cells, that is, as a group of cells which share a common ancestry, have similar abnormalities in the expression and/or content of their genetic material, and often grow in a continuous and unrestrained manner.[5] However, a recent study has found a common genetic abnormality in some of the cells in most PF/FM tumors. This suggests that PF/PM are, in at least most cases, neoplastic but nonetheless self-limiting and/or spontaneously reversing disorders. That is, they are examples of "transient neoplasms." In all events, PF/PM lesions are benign tumor growths that do not metastasize.[6]

PF/PM lesions may grow at alarming rates,[3] exhibit abnormal histopathologies (e.g. high numbers and overcrowding of cells), and have other elements that are suggestive of a malignancy.[7] Consequently, they have been mistakenly diagnosed as undifferentiated pleomorphic sarcoma (also termed malignant fibrous histiocytoma), rhabdomyosarcoma,[1] or other types of sarcoma[8] and treated unnecessarily with aggressive measures used for such malignancies, e.g. wide surgical resection, radiation therapy, and chemotherapy.[1][9] The majority of PF/PM lesions are successfully treated with strictly conservative and supportive measures.[6]

Presentation

edit

PF/PM lesions occur primarily in middle-aged and older adults[6] (peak age of onset 50 to 55 years/old) with no appreciable differences in their incidences between males and females.[1] Only very rare cases have been reported in children and adolescents.[2] In up to 20% to 30% of cases, these lesions are apparently preceded by some sort of mechanical injury.[1] Individuals commonly present within 1–3 weeks[1] or, rarely, longer times (e.g. 3 months)[8] of noticing a rapidly growing, small (<5 cm. in size) mass or swelling in the subcutaneous tissues or muscles[1] of an extremity or, less commonly, the trunk wall, head, or neck areas.[6] Uncommonly, the lesions are ulcerated.[3] In rare cases, the lesions are extensive and highly disruptive, e.g. PF/PM has presented with lockjaw, i.e. a reduced ability to open the jaw due to a PF/PM lesion infiltrating and disrupting the function of the muscles of mastication (i.e. jaw-opening muscles).[1] PF/PM lesions may be associated with tenderness, pain,[6] and/or very rarely fever of unknown cause.[1] The lesions may be regressing at the time of diagnose or, in rare instances, spontaneously regress beginning immediately after being biopsied.[10] Very rarely, these lesions have evolved rapidly, compromised local blood flow,[3] and/or recurred at the site where they were removed by conservative local surgical excision. However, PF/MF lesions do not metastasize to distant tissues.[2]

Pathology

edit

PF/PM lesions are poorly circumscribed masses[6] which on histopathological microscopic analyses consist of bland fibroblastic and myofibroblastic spindle-shaped cells[3] mixed with variable proportions of giant epithelioid ganglion cell-like cells.[6] These cells are in a myxoid (i.e. a clear, mucus-like substance which when prepared using a standard H&E staining method appears more blue or purple than the red color of normal tissues) to fibrous (i.e. high collagen fiber content) background[6] which may contain areas of necrosis (i.e. sites of dead cells).[2] Overall, the cells in these lesions are amphophilic or basophilic, may have vacuole-laden cytoplasm, are slowly multiplying based on their proliferative index, and lack atypical mitosis figures that might be suggestive of a malignancy. The presence of at least some giant epithelioid ganglion-like cells[10][6] within this histopathological background are necessary and definitive evidence that a swelling or tumor is a PF/PM. Compared to adult cases, pediatric cases of PF/PM lesions are often better delineated from normal tissue, are more cellar, have a greater frequency of necrosis sites,[2] contain diffuse sheets of epitheliod ganglion-like cell cells but lack a spindle-shaped cell component, and are lobulated.[6] The spindle-shaped cells, but not epithelioid ganglion-like cell cells, in proliferative myositis lesions express smooth muscle actin proteins.[8]

Genetics

edit

A recent study conducted in Japan found that the tumor tissues of 5 of 5 analyzed adult patients with PF/PM lesions expressed a high level of an abnormal c-Fos protein. This protein was a fusion protein formed by a chromosomal translocation between two disparate genes: the c-Fos gene[11] (also termed FOS), a potential cancer-causing oncogene, normally located at chromosome band 24.3 on the long arm (i.e. q arm) of chromosome 14 and the VIM gene,[12] normally located at band 13 on the short arm (i.e. p arm) of chromosome 10. The FOS:VIM fusion gene along with its c-Fos-VIM protein (which possesses uncontrolled c-Fos activity) are associated with the development and/or progression of some other fibroblastic and myofibroblastic tumors as well as malignant sarcomas. The FOS:VIM fusion gene and c-Fos-VIM fusion protein were found primarily in the epithelioid ganglion-like cell cells but mostly absent in the spindle-shaped cells of these lesion. The tumor of the single young person (1 year/old male) analyzed showed no evidence of this fusion gene or fusion protein. While these findings must be confirmed in a larger number of individuals, they do suggest that: 1) the FOS:VIM fusion gene and c-Fos-VIM fusion protein may contribute to the development of PF/PM in adults; 2) this fusion gene and its protein product may not be involved in childhood PF/PM tumors which also differ from adult PF/PM tumors in their histopathology (see the above Pathology section); and 3) the epithelioid ganglion-like cells but not spindle-shaped cells or any other cell types in adult PF/PM tumors may be neoplastic.[6] It is further suggested that spontaneously reversing and self-limiting PF/PM tumors in adults are "transient neoplasms" similar to other theorized transient neoplasms[6] such as nodular fasciitis[13][14] myositis ossificans,[15] aneurysmal bone cyst, and giant cell lesion of small bones.[16] Two other genetic abnormalities have been reported in PF/PM tumors: trisomy 2 (i.e. the presence of an extra chromosome 2) in the tumor cells of two cases[17][18] and a translocation of genetic material between band 23 on the long arm of chromosome 6 and band 32 on the long arm of chromosome 14 in the tumor cells of one case.[19] Neither of these abnormalities have been validated, further characterized, or confirmed in other studies.[6] Finally, 2 of 20 proliferative fasciitis tumors tested positive for the abnormal expression of FOSB protein, a product of the FOSB oncogene.[20][21][22]

Diagnosis

edit

The diagnosis of PF/PM lesions depends or their presentation and, most importantly, their histopathology showing the presence of epithelioid ganglion-like cell cells. The presence of at least some of these signature cells in a lesion with an appropriate presentation in either a soft tissue or muscle tissue is considered definitive evidence that the lesion is a PF/PM.[10][6] Analyses of tumor tissues for c-FOS may turn out be another useful marker for PF/PM.[6]

Treatment and prognosis

edit

The primary treatment for PF/PM lesions is watchful waiting, i.e. following the lesions for spontaneous regression or any possible complications that require surgical intervention. Symptomatic therapy such as analgesics, e.g. nonsteroidal anti-inflammatory drugs, may be required to treat pain or rare cases of fever.[1] Rare PF/PM lesions may require surgical excision when, for example, they interfere with blood flow[23] or produce a painful, poorly functional hand due to the tumor inducing a trigger finger,[24] Surgical resections in these cases are generally curative.[25]

References

edit
  1. ^ a b c d e f g h i j Nishi TM, Yamashita S, Hirakawa YN, Katsuki NE, Tago M, Yamashita SI (September 2019). "Proliferative Fasciitis/Myositis Involving the Facial Muscles Including the Masseter Muscle: A Rare Cause of Trismus". The American Journal of Case Reports. 20: 1411–1417. doi:10.12659/AJCR.917193. PMC 6777384. PMID 31551403.
  2. ^ a b c d e Porrino J, Al-Dasuqi K, Irshaid L, Wang A, Kani K, Haims A, Maloney E (June 2021). "Update of pediatric soft tissue tumors with review of conventional MRI appearance-part 1: tumor-like lesions, adipocytic tumors, fibroblastic and myofibroblastic tumors, and perivascular tumors". Skeletal Radiology. 51 (3): 477–504. doi:10.1007/s00256-021-03836-2. PMID 34191084. S2CID 235678096.
  3. ^ a b c d e Brooks JK, Scheper MA, Kramer RE, Papadimitriou JC, Sauk JJ, Nikitakis NG (April 2007). "Intraoral proliferative myositis: case report and literature review". Head & Neck. 29 (4): 416–20. doi:10.1002/hed.20530. PMID 17111425. S2CID 9698761.
  4. ^ Sbaraglia M, Bellan E, Dei Tos AP (April 2021). "The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives". Pathologica. 113 (2): 70–84. doi:10.32074/1591-951X-213. PMC 8167394. PMID 33179614.
  5. ^ Wong NL, Di F (December 2009). "Pseudosarcomatous fasciitis and myositis: diagnosis by fine-needle aspiration cytology". American Journal of Clinical Pathology. 132 (6): 857–65. doi:10.1309/AJCPLEPS44PJHDPP. PMID 19926576.
  6. ^ a b c d e f g h i j k l m n o Makise N, Mori T, Motoi T, Shibahara J, Ushiku T, Yoshida A (May 2021). "Recurrent FOS rearrangement in proliferative fasciitis/proliferative myositis". Modern Pathology. 34 (5): 942–950. doi:10.1038/s41379-020-00725-2. PMID 33318581. S2CID 228627775.
  7. ^ Satish S, Shivalingaiah SC, Ravishankar S, Vimalambika MG (October 2012). "Fine needle aspiration cytology of pseudosarcomatous reactive lesions of soft tissues: A report of two cases". Journal of Cytology. 29 (4): 264–6. doi:10.4103/0970-9371.103949. PMC 3543599. PMID 23326034.
  8. ^ a b c Gan S, Xie D, Dai H, Zhang Z, Di X, Li R, Guo L, Sun Y (2019). "Proliferative myositis and nodular fasciitis: a retrospective study with clinicopathologic and radiologic correlation". International Journal of Clinical and Experimental Pathology. 12 (12): 4319–4328. PMC 6949867. PMID 31933833.
  9. ^ Meis JM, Enzinger FM (April 1992). "Proliferative fasciitis and myositis of childhood". The American Journal of Surgical Pathology. 16 (4): 364–72. doi:10.1097/00000478-199204000-00005. PMID 1566969. S2CID 20591490.
  10. ^ a b c Forcucci JA, Bruner ET, Smith MT (January 2016). "Benign soft tissue lesions that may mimic malignancy". Seminars in Diagnostic Pathology. 33 (1): 50–9. doi:10.1053/j.semdp.2015.09.007. PMID 26490572.
  11. ^ "FOS Fos proto-oncogene, AP-1 transcription factor subunit [Homo sapiens (Human)] - Gene - NCBI".
  12. ^ "VIM vimentin [Homo sapiens (Human)] - Gene - NCBI".
  13. ^ Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L, Ye Y, Lau AW, Wang X, Oliveira AM (October 2011). "Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion". Laboratory Investigation. 91 (10): 1427–33. doi:10.1038/labinvest.2011.118. PMID 21826056.
  14. ^ Oliveira AM, Chou MM (January 2014). "USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis". Human Pathology. 45 (1): 1–11. doi:10.1016/j.humpath.2013.03.005. PMID 23769422.
  15. ^ Švajdler M, Michal M, Martínek P, Ptáková N, Kinkor Z, Szépe P, Švajdler P, Mezencev R, Michal M (June 2019). "Fibro-osseous pseudotumor of digits and myositis ossificans show consistent COL1A1-USP6 rearrangement: a clinicopathological and genetic study of 27 cases". Human Pathology. 88: 39–47. doi:10.1016/j.humpath.2019.02.009. PMID 30946936. S2CID 133544364.
  16. ^ Flucke U, Shepard SJ, Bekers EM, Tirabosco R, van Diest PJ, Creytens D, van Gorp JM (August 2018). "Fibro-osseous pseudotumor of digits - Expanding the spectrum of clonal transient neoplasms harboring USP6 rearrangement" (PDF). Annals of Diagnostic Pathology. 35: 53–55. doi:10.1016/j.anndiagpath.2018.05.003. PMID 29787930. S2CID 44139358.
  17. ^ Bridge JA, Dembinski A, DeBoer J, Travis J, Neff JR (March 1994). "Clonal chromosomal abnormalities in osteofibrous dysplasia. Implications for histopathogenesis and its relationship with adamantinoma". Cancer. 73 (6): 1746–52. doi:10.1002/1097-0142(19940315)73:6<1746::aid-cncr2820730632>3.0.co;2-w. PMID 8156503.
  18. ^ Ohjimi Y, Iwasaki H, Ishiguro M, Isayama T, Kaneko Y (September 1994). "Trisomy 2 found in proliferative myositis cultured cell". Cancer Genetics and Cytogenetics. 76 (2): 157. doi:10.1016/0165-4608(94)90470-7. PMID 7923069.
  19. ^ McComb EN, Neff JR, Johansson SL, Nelson M, Bridge JA (October 1997). "Chromosomal anomalies in a case of proliferative myositis". Cancer Genetics and Cytogenetics. 98 (2): 142–4. doi:10.1016/s0165-4608(96)00428-1. PMID 9332481.
  20. ^ "FOSB FosB proto-oncogene, AP-1 transcription factor subunit [Homo sapiens (Human)] - Gene - NCBI".
  21. ^ "WikiGenes - Collaborative Publishing".
  22. ^ Hung YP, Fletcher CD, Hornick JL (May 2017). "FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma". The American Journal of Surgical Pathology. 41 (5): 596–606. doi:10.1097/PAS.0000000000000795. PMID 28009608. S2CID 35638467.
  23. ^ Haloi AK, Seith A, Chumber S, Bandhu S, Panda SK, Mannan SR (January 2004). "Case of the season: proliferative myositis". Seminars in Roentgenology. 39 (1): 4–6. doi:10.1016/j.ro.2003.10.001. PMID 14976833.
  24. ^ Vlaic J, Fattorini MZ, Dukaric N, Tomas D (September 2020). "Proliferative fasciitis: A rare cause of disturbances in an adolescent hand". Acta Orthopaedica et Traumatologica Turcica. 54 (5): 557–560. doi:10.5152/j.aott.2020.19033. PMC 7646621. PMID 32442126.
  25. ^ Rosenberg AE (April 2008). "Pseudosarcomas of soft tissue". Archives of Pathology & Laboratory Medicine. 132 (4): 579–86. doi:10.5858/2008-132-579-POST. PMID 18384209.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Proliferative_fasciitis_and_proliferative_myositis&oldid=1188125373"